At a glance
ClinicalIndex Comparison RecordN/AUnknown· 40 target
Drug / intervention
Oligopin® +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Study to Determine the Safety and Efficacy of Oligopin® on Metabolic Risk Factors in Subjects With Metabolic Syndrome
In Brief
A clinical study evaluating Oligopin® and Placebo for Metabolic Syndrome. Targeting 40 participants across 1 site.
Detailed Summary
The safety and efficacy of Oligopin® will be compared against a placebo to evaluate the effect on metabolic risk factors in subjects with metabolic syndrome. During the 84-day study period it is hypothesized that HDL cholesterol will increase and systolic blood pressure will decrease therefore lowering CVD risk factors after supplementation with Oligopin®. Additionally, it is hypothesized that Oligopin® supplementation will reduce fasting glucose levels.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesCanada
CollaboratorsKGK Science Inc.
Timeline
N/AUnknownOverdue
202120222023202420252026
Enrollment StartJun 2020
First PostedJul 2020
Primary CompletionOct 2021
Study CompletionJan 2022
TodayJul 2026
First PostedJul 28, 2020
Enrollment StartJun 24, 2020
Primary CompletionOct 19, 2021
Study CompletionJan 10, 2022
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 5.9 years ago
Interventions
Oligopin®dietary
French Maritime Pine Bark Extract - 100mg/day
Placebodietary
Maltodextrin